You are missing my point and that is likely my fault... My point is that 2mg dosing, isn't and hasn't been what is holding "any pharma" back from securing a seat at the table to market this.
PAR. SP, page-556
-
- There are more pages in this discussion • 697 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.81M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 29.0¢ | 25.5¢ | $430.3K | 1.585M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 36162 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |